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Tumor Necrosis Factor and Tuberculosis
Philana Ling Lin1,2,4, Hillarie L. Plessner2,4, Nikolai N. Voitenok3 and JoAnne L. Flynn2
Tumor necrosis factor (TNF) plays a major role in the initial and long-term control of tuberculosis. The
mechanisms by which this cytokine contributes to the control of Mycobacterium tuberculosis infection are
numerous and therefore difficult to dissect. TNF is important in macrophage activation as well as cell
recruitment to the site of infection. It is the primary signal important in granuloma formation, as neutralization
of this cytokine leads to lack of control of initial or chronic infection, and loss of granuloma structure. In
humans treated with TNF-neutralizing drugs, an increased susceptibility to tuberculosis, as well as other
infectious diseases, is observed. We are using animal models to understand how TNF neutralization by these
drugs can lead to reactivation of tuberculosis.
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INTRODUCTION
Tuberculosis is caused by a bacterium, Mycobacterium
tuberculosis. There are 8 million new cases of tuberculosis
worldwide and approximately 2 million deaths owing to this
disease each year. Primary tuberculosis (disease within 2
years of exposure) occurs in only a small percentage of
infected people (B5%). The majority of infected persons
(490%) will develop a state of latent infection in which there
are no signs or symptoms present, but a positive delayed type
hypersensitivity reaction is observed by tuberculin skin test.
Only patients with active tuberculosis disease are contagious,
not latently infected individuals. It is widely believed that
latently infected people do not clear the infection, but
contain and control it at a low level in the lungs or other
organs. A small percentage (10%) of latently infected subjects
will eventually reactivate the infection and present with
active tuberculosis. The factors involved in maintaining the
infection in the latent state, and preventing reactivation are
not well understood. It is known that HIV infection is a major
risk factor for developing tuberculosis, supporting the
generally held belief that CD4 T cells are necessary for
immune-mediated control of this infection. Immune suppres-
sion in general (such as from corticosteroids) can lead to
reactivation of latent tuberculosis (Garay, 2004). Increased
age (and the accompanying waning immune response) is also
a risk factor for tuberculosis. More recent data in humans
undergoing tumor necrosis factor (TNF)-modulation treat-
ment for chronic inflammatory diseases strongly support the
existing experimental data that TNF is necessary for prevent-
ing reactivation tuberculosis (Keane et al., 2001). The
mechanisms by which TNF is important in initial and long-
term control of tuberculosis are not clear, and are likely to be
numerous. Our lab has focused on understanding how TNF
participates in the initiation of the immune response to M.
tuberculosis, as well as the control of infection during the
latent or chronic phase.
M. tuberculosis bacilli are transmitted via the respiratory
route, and the initial interaction of the organism with the host
is through alveolar macrophages in the airways. The
organism then transits to the parenchyma of the lung,
replicating within resident macrophages. This interaction
with macrophages initiates an inflammatory response,
including production of TNF, IL-12, IL-1, IL-6, and various
chemokines (reviewed by Flynn and Chan, 2001). These
molecules induce other cells to enter the lungs, including
monocytes (which differentiate into macrophages), neutro-
phils, and eventually lymphocytes. Dendritic cells, specia-
lized antigen-presenting cells, can ingest M. tuberculosis,
which results in maturation of the dendritic cell (Bodnar
et al., 2001), and travel to the regional lymph nodes (Bhatt
et al., 2004). In the lymph nodes, the dendritic cells prime
CD4þ and CD8þ T cells (Lazarevic et al., 2003). The newly
activated T cells specific for mycobacterial antigens then
travel back to the lungs and participate in granuloma
formation. CD4 and CD8T cells are important in the immune
response to M. tuberculosis, and function by secreting
cytokines (including those that can activate macrophages,
such as IFN-g and TNF) (Serbina and Flynn, 1999), and in
the case of CD8 T cells, either destroying infected cells or
directly killing the intracellular bacteria by secreting the
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molecule granulysin into infected macrophage (Stenger et al.,
1998).
Granulomas in tuberculosis
Although not unique to mycobacterial infections, the
granuloma is the hallmark of tuberculosis. This organized
collection of immune cells is maintained by the persistent
presence of antigen. The tuberculous granuloma is typically
composed of macrophages (often epithelioid), multinucleated
giant cells (formed by fusion of macrophages), lymphocytes
(both CD4þ and CD8þ T cells, and B cells), neutrophils,
and sometimes fibroblasts. In human tuberculosis, the
granulomas frequently, although not always, have a necrotic
center, known as caseous necrosis. The bacteria appear to
survive within macrophages and in the caseous center of the
granuloma. The status of the bacteria within the granuloma
has not been well defined.
From the host point of view, the granuloma functions as an
immune microenvironment to contain the M. tuberculosis
bacilli. This allows a localized inflammatory response
focused to the site of the pathogen, rather than a disseminated
response that could potentially damage larger uninfected
areas of the lungs. In addition, the inflammatory cells (such as
T cells and macrophages) are brought into close proximity to
the pathogen to facilitate interaction. It is believed that the
granuloma may also provide a physical barrier that contains
the organism, although this is more difficult to demonstrate.
The caseous center may inhibit replication of the bacteria,
and perhaps contribute to control of the infection. In any
event, it seems likely that properly functioning granulomas
limit the spread of the infection within the lung as well as to
other organs in the body.
Although the granuloma is believed to be critical to the
immunologic and physical control and containment of M.
tuberculosis, it seems that the bacillus benefits from this
structure as well suggesting co-evolution of host and
pathogen (Flynn and Chan, 2005). Although it is likely that
a large proportion of the bacilli within a granuloma can be
killed, some can survive and may result in reactivation at the
site of the granuloma. In older human studies, M. tuberculosis
could be grown from granulomas isolated from latently
infected lungs (Vandiviere et al., 1956). Thus, the granuloma
likely provides a ‘‘shelter’’ for the organism, and the bacillus
has probably evolved many mechanisms to survive within the
granuloma (Russell, 2001). The benefit to the microbe is that
the granuloma provides a place to survive until conditions are
favorable for growth and potential reactivation. Years after
the initial infection, reactivation to active tuberculosis
renders the host contagious, resulting in transmission of M.
tuberculosis to new (mostly likely uninfected) contacts. This
strategy contributes to the remarkable success of this
pathogen, as it is estimated that 2 billion people (or roughly
one-third of the world’s population) are currently infected
with M. tuberculosis.
TNF and granuloma formation
The cytokine TNF is critical for granuloma formation, and
also appears to be required for granuloma maintenance. This
cytokine has several roles to play in tuberculosis, and each
function is likely to be important in control of M. tuberculosis
infection. TNF is an important signal for macrophage
activation, in conjunction with IFN-g (Flesch and Kaufmann,
1990). It is also important in mediating apoptosis of infected
cells, at least in vitro (Keane et al., 2000). Although the role of
apoptosis in vivo in tuberculosis remains to be demonstrated,
destruction of an infected cell via apoptotic mechanisms
leads to inhibition of bacterial growth (Gan et al., 2005; Chen
et al., 2006). Inhibition of TNF also inhibits apoptosis in vitro
(Keane et al., 2000).
Mice deficient in TNF are completely unable to control M.
tuberculosis infection, and granulomas do not form properly
in their lungs (Flynn et al., 1995; Bean et al., 1999). Mice in
which TNF is neutralized during the chronic phase of
infection also rapidly succumb to disease, which in this
model appears to be more related to substantial pathology in
the lungs than extremely high bacterial numbers (Mohan
et al., 2001). Histologically, the aggregation of cells in the
mouse lungs was disrupted by neutralization of TNF, and the
cells that continued to infiltrate the lungs appeared to lack the
necessary signals to aggregate and focus into granulomas
(Mohan et al., 2001). This led to pathology that impaired the
lung function and contributed to the death of the mice. The
mouse data, as well as data in other systems, led to the
hypothesis that TNF was important in orchestrating granulo-
ma formation and maintenance.
TNF and chemokines in tuberculosis
Molecules thought to be important in directing cell migration
include chemokines and adhesion molecules. We performed
in vivo and in vitro studies with macrophages to demonstrate
that certain inflammatory chemokines, including CCL5
(RANTES), CXCL9 (MIG), and CXCL10 (IP-10) were strongly
induced following M. tuberculosis infection in the mouse and
non-human primate models of tuberculosis (Algood et al.,
2004). Expression was in part dependent on TNF production
induced by infection as well. When TNF was neutralized in
vitro or in vivo, chemokine expression was also reduced
(Algood et al., 2004; unpublished data). This suggested that
changes in chemokine expression could lead to a reduction
in the ability of cells to aggregate and form granulomas, or to
stay in close proximity in an already formed granuloma.
However, it is unlikely that these chemokines are the only
TNF-dependent mediators of granuloma formation because
mice deficient in the receptors for these chemokines (CCR5/
, CXCR3/) or in which the ligands are deficient or
neutralized (CXCL10/ and anti-CXCL9 antibody treated)
are not noticeably impaired in their ability to control an M.
tuberculosis infection (Seiler et al., 2003; Algood and Flynn,
2004; Algood et al., 2004). This supports that TNF has
numerous roles during M. tuberculosis infection and several
of these mechanisms may be operative in controlling
granuloma formation and maintenance.
TNF neutralization in the mouse model of tuberculosis
C57BL/6 mice infected with M. tuberculosis by the aerosol
route control the infection by 4 weeks, although cannot
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reduce the bacterial numbers; the mice remain chronically
infected with a fairly high bacterial burden (B106 colony-
forming units per lung). The infection remains at a stable
level, although the pathology is progressive. All mice
succumb to the infection eventually, although some mice
can live up to a year post-infection.
In our previous studies, we have demonstrated that
treatment of mice with chronic tuberculosis (4–6 months
post-infection) with MP6-XT22, an anti-TNF antibody,
resulted in rapid fulminant disease, characterized by dis-
organized granulomas and a modest increase in bacterial
burden, and mice succumbed within 3 weeks of antibody
treatment (Mohan et al., 2001; Algood et al., 2004).
Use of anti-TNF-modulating agents for the treatment of
inflammatory diseases such as Crohn’s disease has been
associated with an increased risk of tuberculosis in human
clinical data. This is presumed to be due to reactivation of
latently infected individuals (Keane et al., 2001). Some data
suggest that the risk of tuberculosis is less with the TNF
receptor-2 fusion protein (etanercept), used to treat rheuma-
toid arthritis (Wallis et al., 2004). To investigate this, we used
a mouse version of etanercept, mTNF receptor p75-IgG in our
mouse model of chronic tuberculosis. In preliminary experi-
ments, in contrast to anti-TNF antibody, treatment with
receptor fusion did not impair the ability of the mouse to
control the chronic infection (unpublished data). The
differential outcomes between antibody or receptor fusion
protein in this model provide a system in which to not only
identify the mechanisms by which these drugs may con-
tribute to tuberculosis or reactivation of tuberculosis, but also
to learn more about the mechanisms by which TNF is
necessary to maintain control of the infection. The possible
explanations for differences in the effects of the drugs on
chronic tuberculosis in the mouse include differential binding
of TNF at the site of infection, different affinities and avidities
for membrane-bound or soluble TNF between the drugs,
apoptosis of cells owing to binding of antibody, and
penetration of the anti-TNF drugs to and within the
granuloma. Although there are differences in dissociation
constants for TNF among the anti-TNF drugs (Scallon et al.,
2002), the circulating concentration of all of the drugs is in
excess to the TNF levels normally observed. However, the
levels of drug relative to levels of TNF in the lungs and/or
granulomas are not known, and may account for differences
in outcome in mice as well as humans. We will take
advantage of our mouse model to investigate these possibi-
lities.
TNF in the non-human primate model of tuberculosis
We have also developed a non-human primate model of
tuberculosis (Capuano et al., 2003; Flynn et al., 2005).
Cynomolgus macaques are infected with a low dose of M.
tuberculosis directly into the lungs via bronchoscope.
Approximately half the monkeys develop primary tubercu-
losis within the first 6 months, and half the monkeys have
latent tuberculosis. This latent infection can reactivate
months to years later, although most of the monkeys to date
remain latent for at least a year. These outcomes are based on
clinical signs as well as microbiologic monitoring. In
particular, this is the only animal model with truly latent M.
tuberculosis infection. The clinical outcomes and pathology
of the infection are extremely similar to human tuberculosis.
Organized granulomas, as well as the full spectrum of
granuloma types, are seen in monkeys with active tubercu-
losis, and the number of bacteria per granuloma is variable.
In monkeys with latent infection, the granulomas are
organized, often fibrotic and/or calcified, and have very few
bacteria.
TNF is expressed by cells within the granulomas, as
observed by in situ hybridization (Fuller et al., 2003) and
messenger RNA analysis (unpublished data). As the cyno-
molgus monkey provides a true model of latent infection,
unlike the mouse, we are studying whether neutralization of
TNF could reactivate the latent infection. The first anti-TNF
antibody marketed for use in human chronic inflammatory
disease, infliximab, does not neutralize TNF in macaques, so
we could not use this antibody to examine the reliance on
TNF for maintaining latency in this model. We began our
studies with a mouse antibody effective in neutralizing
human and macaque TNF (Song et al., 2002). Signs of
reactivation tuberculosis upon necropsy of these monkeys
6–8 weeks after antibody treatment was observed (unpub-
lished data). However, because the antibody is murine-
derived, the monkeys developed an antibody response
against the administered antibody, thus limiting the use of
this reagent. Further studies with additional reagents are
underway, including a TNF receptor fusion molecule similar
to etanercept and a different antibody against TNF that is now
available for human use (adalimumab). Adalimumab is a
humanized antibody that neutralizes macaque TNF, and thus
can be used in our model. These reagents will provide
information about the requirements for TNF in maintaining
the latent granulomas and containing infection, as well as the
potential to identify mechanisms by which TNF functions in
the response against tuberculosis in a model that is
remarkably similar to human tuberculosis.
CONCLUSION
In summary, TNF plays an important role in the granuloma-
tous response against tuberculosis. The mechanisms by
which TNF acts to control tuberculosis, as well as directing
cells to the site of infection, are not clearly defined. A
dependence on TNF for production of some chemokines
present within the granuloma has been demonstrated.
However, each of these chemokines individually does not
seem to control granuloma formation. Adhesion molecules
may also be regulated by TNF and crucial in granuloma
formation and control of infection (Johnson et al., 1998;
Schreiber et al., 2006). Use of various TNF-neutralizing drugs
in the mouse and monkey models of tuberculosis provide us
with the opportunity to understand the function of these
molecules, and more importantly, the function of TNF in both
initial and latent M. tuberculosis infection.
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